Physician
Pulmonology
Dr. Mark W. Geraci, MD
|
|
Give Review
Mark Geraci practices Pulmonology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Mark Geraci is a published doctor. He has 89 papers published. The most current publication "Primary pulmonary hypertension between inflammation and cancer." He accepts Medicare.
Publications
- Blood transcriptional biomarkers for active TB among US patients: A case-control study with systematic cross-classifier evaluation.
- Transcriptional Impact of Rare and Private Copy Number Variants in Hypoplastic Left Heart Syndrome.
- Assessment of microRNA differential expression and detection in multiplexed small RNA sequencing data.
- Relationship of DNA Methylation and Gene Expression in Idiopathic Pulmonary Fibrosis (IPF).
- Functional Prostacyclin Synthase Promoter Polymorphisms: Impact in Pulmonary Arterial Hypertension.
- Application of SNP microarrays to the Genome-wide Analysis of Chromosomal Instability in Premalignant Airway Lesions.
- Genetics and genomics of Pulmonary arterial hypertension.
- Protective Role of IL6 in Vascular Remodeling in Schistosoma-Pulmonary Hypertension.
- Integrating molecular genetics and systems approaches to Pulmonary vascular diseases.
- Increased lymphatic vessel length is associated with the fibroblast reticulum and Disease severity in usual interstitial pneumonia and nonspecific interstitial pneumonia.
- TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of Cancer cells.
- Manipulation of Pulmonary prostacyclin synthase expression prevents murine lung cancer.
- Overexpression of matrix metalloproteinase-7 in Pulmonary fibrosis.
- Gene expression profiles in Pulmonary hypertension.
- Janus face of vascular endothelial growth factor: the obligatory survival factor for Lung vascular endothelium controls precapillary artery remodeling in severe pulmon...
- Oxygen-dependent regulation of Pulmonary circulation.
- Pigment epithelium-derived factor in idiopathic Pulmonary fibrosis: a role in aberrant angiogenesis.
- Prostacyclin in human non-small cell Lung cancers.
- Gene microarray analysis of peripheral blood cells in Pulmonary arterial hypertension.
- Emphysema Lung tissue gene expression profiling.
- Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.
- Recombinant human activated protein C reduces human endotoxin-induced Pulmonary inflammation via inhibition of neutrophil chemotaxis.
- Signaling through the prostaglandin I2 receptor IP protects against Respiratory syncytial virus-induced illness.
- Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for Lung tumorigenesis in mice.
- Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell Lung can...
- Practical Cancer genetics, genomics and proteomics.
- Analysis of orthologous gene expression between human Pulmonary adenocarcinoma and a carcinogen-induced murine model.
- The expression of prostacyclin synthase is decreased in the small Pulmonary arteries from patients with emphysema.
- Microarray analysis of peripheral blood cells in Pulmonary arterial hypertension, surrogate to biopsy.
- Prostacyclin synthase promoter regulation and familial Pulmonary arterial hypertension.
- Attenuation of the Pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A2 null mice.
- Human Lung project: evaluating variance of gene expression in the human Lung.
- Functional and genomic changes induced by alveolar transmigration in human neutrophils.
- Baseline gene expression predicts sensitivity to gefitinib in non-small cell Lung cancer cell lines.
- Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine Lung tumorigenesis.
- Prostacyclin synthase in smoking-related lung Disease.
- Lung tissue banks for gene expression studies.
- Gene expression profiling in Pulmonary hypertension.
- Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells.
- Prostacyclin prevents Pulmonary endothelial cell apoptosis induced by cigarette smoke.
- Genetic and epigenetic regulation of the human prostacyclin synthase promoter in Lung cancer cell lines.
- Prostacyclin in Lung cancer.
- MicroRNA in Lung cancer.
- Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of Lung cancer cel...
- Hypoxia induces different genes in the Lungs of rats compared with mice.
- Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in Pulmonary hypertension and affects endothelial cell growth.
- Expression of human herpesvirus 8 in primary Pulmonary hypertension.
- Circulating endothelial cells in Pulmonary hypertension.
- A macrophage gene expression signature defines a field effect in the Lung tumor microenvironment.
- Human herpesvirus-8 infection of primary Pulmonary microvascular endothelial cells.
- Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung Disease.
- Prostacyclin prevents murine Lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.
- Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against Lung cancer progression and metastasis.
- Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner.
- Genomics of Pulmonary arterial hypertension: implications for therapy.
- The case for 24/7 in-house intensivist coverage.
- Somatic chromosome abnormalities in the lungs of patients with Pulmonary arterial hypertension.
- Increased expression of growth differentiation factor-15 in systemic sclerosis-associated Pulmonary arterial hypertension.
- Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated Pulmonary hypertension.
- Significant downregulation of platelet gene expression in metastatic Lung cancer.
- Oral iloprost improves endobronchial dysplasia in former smokers.
- PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression.
- Con: the case for expanded Lung cancer research support.
- Extracellular superoxide dismutase haplotypes are associated with acute Lung injury and mortality.
- HOX genes in human lung: altered expression in primary Pulmonary hypertension and emphysema.
- Gene expression patterns in the lungs of patients with primary Pulmonary hypertension: a gene microarray analysis.
- Rat prostacyclin synthase. Cloning and regulation of gene expression in the Lung.
- Primary Pulmonary hypertension between inflammation and cancer.
- Prostacyclin synthase expression is decreased in lungs from patients with severe Pulmonary hypertension.
- Surfactant protein C promoter-driven expression of T1-alpha induces Lung inflammation.
- Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice.
- Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic Pulmonary hypertension.
- Expression of angiogenesis-related molecules in plexiform lesions in severe Pulmonary hypertension: evidence for a process of disordered angiogenesis.
- Primary Pulmonary hypertension, Castleman''s disease and human herpesvirus-8.
- Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
- Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in Lung carcinoma.
- Genomic approaches to research in Pulmonary hypertension.
- Severe Pulmonary hypertension after the discovery of the familial primary Pulmonary hypertension gene.
- Prostacyclin receptor-dependent modulation of Pulmonary vascular remodeling.
- Spatial and temporal analysis of gene expression during growth and fusion of the mouse facial prominences.
- Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal Cancer.
- Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.
- Anti-growth factor therapy for Lung cancer.
- Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary arterial hypertension suggests pathways relevant to disease penetrance.
- Strategic plan for Lung vascular research: An NHLBI-ORDR Workshop Report.
- Novel bombesin-like peptide binding proteins from Lung.
- Effects of Chronic estrogen-receptor blockade on ovine perinatal pulmonary circulation.
- Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.
Schools
Johns Hopkins University School Of Medicine
Brigham and Women39s HospitalMassachusetts General Hospital Program
University Of Colorado University Hospital Program
Procedures Preformed
- Bronchoscopy
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Alkalosis
- Asthma
- Atelectasis
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
Massachusetts General Hospital -
Johns Hopkins University School of Medicine
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1528158201 | |
| NPPES Provider LastName | GERACI | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 167.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 13.17 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528158201 |
| Last Name Of The Provider | GERACI |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Chakradhar Kotaru, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Todd M. Bull, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph M. Forrester, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. James C. Lavelle IV, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Marvin Schwarz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen P. Malkoski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madison Macht, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David A. Schwartz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan J. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clifford W. Zwillich, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jessica B. Badlam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd Grazia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara J. Mould, MD
This Doctor is OpenDoctor Recommended.
|